Publications (193) JAVIER PUENTE VÁZQUEZ publications

filter_list

2026

  1. Bone health in patients with cancer: a SEOM-SEIOMM consensus review of risk factors, assessment strategies, and management approaches

    Clinical and Translational Oncology

  2. Real-world data on avelumab in first-line maintenance therapy for advanced or metastatic urothelial carcinoma: the SOGUG-AVELUMAB RWD study

    Clinical and Translational Oncology, Vol. 28, Núm. 1, pp. 254-264

  3. Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial☆

    Annals of Oncology, Vol. 37, Núm. 2, pp. 250-259

  4. Treatment patterns in patients with castration-resistant prostate cancer who received darolutamide in the ARAMIS trial in Spain: PARASEC study

    Clinical and Translational Oncology

2025

  1. Abiraterone-Associated Renal Damage in Patients with Advanced Prostate Cancer as a Risk Factor for Mortality and Chronic Kidney Disease

    Journal of Clinical Medicine, Vol. 14, Núm. 21

  2. Association of PD-1, LAG-3 and TIM-3 expression on intratumoral CD8 T-cells with response to atezolizumab in a Real-World-Evidence biomarker study for advanced urothelial carcinoma patients

    OncoImmunology, Vol. 14, Núm. 1

  3. Current Status of Neoadjuvant Treatment Before Surgery in High-Risk Localized Prostate Cancer

    Cancers, Vol. 17, Núm. 1

  4. Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial

    The Lancet, Vol. 406, Núm. 10516, pp. 2221-2234

  5. Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational study

    Clinical and Translational Oncology, Vol. 27, Núm. 5, pp. 2220-2231

  6. Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) in Initial Staging of Prostate Cancer Patients: The Beginning of a New Era

    Medicina (Lithuania), Vol. 61, Núm. 5

  7. Real-world evidence in localized and locally advanced prostate cancer: applying artificial intelligence to electronic health records

    BMC Cancer, Vol. 25, Núm. 1

  8. Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain

    Clinical and Translational Oncology, Vol. 27, Núm. 5, pp. 2232-2240

  9. SEOM–SOGUG clinical guideline for urothelial cancer (2025)

    Clinical and Translational Oncology, Vol. 27, Núm. 11, pp. 4142-4159

  10. The spatial landscape of cancer hallmarks reveals patterns of tumor ecological dynamics and drug sensitivity

    Cell Reports, Vol. 44, Núm. 2

2024

  1. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study

    The Lancet Oncology, Vol. 25, Núm. 1, pp. 46-61

  2. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study

    The Lancet Oncology, Vol. 25, Núm. 1, pp. 29-45

  3. CRISPR/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel essential gene in prostate cancer metastasis

    Cancer Letters, Vol. 588

  4. Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non–small cell lung cancer

    Lung Cancer, Vol. 192

  5. Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study

    European Urology, Vol. 86, Núm. 1, pp. 4-9

  6. Correlation of safety and efficacy of atezolizumab therapy across indications

    Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 11